Hypercalcemia of malignancy results from tumor-produced parathyroid hormone-related protein (PTHrP) which simulates the actions of parathyroid hormone (PTH) and leads to bone loss and kidney calcium retention [55,56,57,58]. Here, PTHLH is linked to hypercalcemia disease.